Skip to main content
Top
Gepubliceerd in: Netherlands Heart Journal 2/2011

01-02-2011 | Original Article

Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia

Auteurs: F. van Nooten, G. M. Davies, J. W. Jukema, A. H. Liem, E. Yap, X. H. Hu

Gepubliceerd in: Netherlands Heart Journal | Uitgave 2/2011

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Objective

This study aims to assess the cost-effectiveness of ezetimibe plus simvastatin (E/S) versus atorvastatin or simvastatin monotherapy as second-line treatment of primary hypercholesterolaemia from the Dutch healthcare perspective.

Methods

The evaluation used a Markov model and patient data from the Dutch EASEGO study in which patients failing to reach goal low-density lipoprotein cholesterol levels on atorvastatin 10 mg or simvastatin 20 mg had their dose doubled or switched to ezetimibe 10 mg plus generic simvastatin 20 mg (E10/S20). The second scenario, based on Dutch guidelines, switched patients from simvastatin 40 mg to atorvastatin 40 mg, or ezetimibe 10 mg was added to simvastatin 40 mg (E10/S40). The key effectiveness input measure was change in total cholesterol/high-density lipoprotein ratio obtained from the EASEGO study. In conformity with published studies linking reduced lipid levels to reduced risk of cardiovascular events, the present model assumed that a lipid decrease with ezetimibe may be a signal for reduced risk of cardiovascular events. Model parameters were derived from published literature. Sensitivity analyses were performed for the key parameters.

Results

In the EASEGO scenario, incremental cost-effectiveness ratio for E10/S20 was €3497/quality-adjusted life-years (QALY) vs atorvastatin 20 mg and €26,417/QALY vs simvastatin 40 mg. In the Dutch guidelines scenario, E10/S40 was dominant (more effective and cost-saving) vs atorvastatin 40 mg. Varying model inputs had limited impact on the cost-effectiveness of E/S.

Conclusions

The analysis showed the cost-effectiveness of E/S versus atorvastatin 20 mg or simvastatin 40 mg (EASEGO scenario) at a threshold of €30,000/QALY and vs atorvastatin 40 mg was dominant (Dutch guidelines). Thus, E/S seems a valuable cost-effective second-line treatment option for patients not attaining lipid treatment goals.
Literatuur
1.
go back to reference Allender S, Scarborough P, Peto V. European Cardiovascular Statistics. Oxford: European Health Network; 2008. Allender S, Scarborough P, Peto V. European Cardiovascular Statistics. Oxford: European Health Network; 2008.
2.
go back to reference Molina JA, Heng BH. Global trends in cardiology and cardiothoracic surgery—an opportunity or a threat? Ann Acad Med Singapore. 2009;38(6):541–5.PubMed Molina JA, Heng BH. Global trends in cardiology and cardiothoracic surgery—an opportunity or a threat? Ann Acad Med Singapore. 2009;38(6):541–5.PubMed
3.
go back to reference Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326(7404):1423.PubMedCrossRef Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326(7404):1423.PubMedCrossRef
4.
go back to reference Dembowski E, Davidson MH. Statin and ezetimibe combination therapy in cardiovascular disease. Curr Opin Endocrinol Diab Obes. 2009;16(2):183–8.CrossRef Dembowski E, Davidson MH. Statin and ezetimibe combination therapy in cardiovascular disease. Curr Opin Endocrinol Diab Obes. 2009;16(2):183–8.CrossRef
5.
go back to reference Kastelein JJ, de Groot E. Ultrasound imaging techniques for the evaluation of cardiovascular therapies. Eur Heart J. 2008;29(7):849–58.PubMedCrossRef Kastelein JJ, de Groot E. Ultrasound imaging techniques for the evaluation of cardiovascular therapies. Eur Heart J. 2008;29(7):849–58.PubMedCrossRef
6.
go back to reference Goldberg AC, Sapre A, Liu J, et al. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2004;79(5):620–9.PubMedCrossRef Goldberg AC, Sapre A, Liu J, et al. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2004;79(5):620–9.PubMedCrossRef
7.
go back to reference Montecucco F, Quercioli A, Mach F. Ezetimibe/simvastatin. Expert Opin Drug Saf. 2009;8(6):715–25.PubMedCrossRef Montecucco F, Quercioli A, Mach F. Ezetimibe/simvastatin. Expert Opin Drug Saf. 2009;8(6):715–25.PubMedCrossRef
8.
go back to reference Bays H, Sapre A, Taggart W, et al. Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia. Curr Med Res Opin. 2008;24(10):2953–66.PubMedCrossRef Bays H, Sapre A, Taggart W, et al. Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia. Curr Med Res Opin. 2008;24(10):2953–66.PubMedCrossRef
9.
go back to reference Brudi P, Reckless JP, Henry DP, et al. Efficacy of ezetimibe/simvastatin 10/40 mg compared to doubling the dose of low-, medium- and high-potency statin monotherapy in patients with a recent coronary event. Cardiology. 2009;113(2):89–97.PubMedCrossRef Brudi P, Reckless JP, Henry DP, et al. Efficacy of ezetimibe/simvastatin 10/40 mg compared to doubling the dose of low-, medium- and high-potency statin monotherapy in patients with a recent coronary event. Cardiology. 2009;113(2):89–97.PubMedCrossRef
10.
go back to reference Perkerson KA, Gillespie EL, Coleman CI. Cost-effectiveness of statin monotherapy and combination therapy with ezetimibe. Conn Med. 2005;69(1):19–22.PubMed Perkerson KA, Gillespie EL, Coleman CI. Cost-effectiveness of statin monotherapy and combination therapy with ezetimibe. Conn Med. 2005;69(1):19–22.PubMed
11.
go back to reference Roeters van Lennep HW, Liem AH, Dunselman PH, et al. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Curr Med Res Opin. 2008;24(3):685–94.PubMedCrossRef Roeters van Lennep HW, Liem AH, Dunselman PH, et al. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Curr Med Res Opin. 2008;24(3):685–94.PubMedCrossRef
12.
go back to reference Reckless JP, Henry P, Pomykaj T, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. Int J Clin Pract. 2008;62(4):539–54.PubMedCrossRef Reckless JP, Henry P, Pomykaj T, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. Int J Clin Pract. 2008;62(4):539–54.PubMedCrossRef
13.
go back to reference Farnier M, Averna M, Missault L, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy—the IN-CROSS study. Int J Clin Pract. 2009;63(4):547–59.PubMedCrossRef Farnier M, Averna M, Missault L, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy—the IN-CROSS study. Int J Clin Pract. 2009;63(4):547–59.PubMedCrossRef
14.
go back to reference Fleg JL, Mete M, Howard BV, et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol. 2008;52(25):2198–205.PubMedCrossRef Fleg JL, Mete M, Howard BV, et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol. 2008;52(25):2198–205.PubMedCrossRef
15.
go back to reference Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359(13):1343–56.PubMedCrossRef Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359(13):1343–56.PubMedCrossRef
16.
go back to reference Cook JR, Yin D, Alemao E, et al. Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway. Pharmacoeconomics. 2004;22 Suppl 3:49–61.PubMed Cook JR, Yin D, Alemao E, et al. Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway. Pharmacoeconomics. 2004;22 Suppl 3:49–61.PubMed
17.
go back to reference Cook JR, Yin D, Alemao E, et al. Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia. Pharmacoeconomics. 2004;22 Suppl 3:37–48.PubMed Cook JR, Yin D, Alemao E, et al. Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia. Pharmacoeconomics. 2004;22 Suppl 3:37–48.PubMed
18.
go back to reference Kohli M, Attard C, Lam A, et al. Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada. Pharmacoeconomics. 2006;24(8):815–30.PubMedCrossRef Kohli M, Attard C, Lam A, et al. Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada. Pharmacoeconomics. 2006;24(8):815–30.PubMedCrossRef
20.
go back to reference Ara R, Pandor A, Tumur I, et al. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries. Clin Ther. 2008;30(8):1508–23.PubMedCrossRef Ara R, Pandor A, Tumur I, et al. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries. Clin Ther. 2008;30(8):1508–23.PubMedCrossRef
21.
go back to reference Soini EJ, Davies G, Martikainen JA, et al. Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland. Curr Med Res Opin. 2010;26(1):25–36.PubMedCrossRef Soini EJ, Davies G, Martikainen JA, et al. Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland. Curr Med Res Opin. 2010;26(1):25–36.PubMedCrossRef
23.
go back to reference Dutch Ministry of Foreign Affairs: Welcome to the Netherlands: Health Care. 2009. Dutch Ministry of Foreign Affairs: Welcome to the Netherlands: Health Care. 2009.
24.
go back to reference D’Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J. 2000;139(2 Pt 1):272–81.PubMed D’Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J. 2000;139(2 Pt 1):272–81.PubMed
25.
go back to reference D’Agostino Sr RB, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286(2):180–7.PubMedCrossRef D’Agostino Sr RB, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286(2):180–7.PubMedCrossRef
26.
go back to reference Oostenbrink J. Handleiding voor kostenonderzoek. Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. CVZ 2005. Oostenbrink J. Handleiding voor kostenonderzoek. Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. CVZ 2005.
27.
go back to reference Greving JP, Buskens E, Koffijberg H, et al. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation. 2008;117(22):2875–83.PubMedCrossRef Greving JP, Buskens E, Koffijberg H, et al. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation. 2008;117(22):2875–83.PubMedCrossRef
28.
go back to reference van Hout BA, Simoons ML. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat? Eur Heart J. 2001;22(9):751–61.PubMedCrossRef van Hout BA, Simoons ML. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat? Eur Heart J. 2001;22(9):751–61.PubMedCrossRef
29.
go back to reference Goodacre S, Nicholl J, Dixon S, et al. Randomised controlled trial and economic evaluation of a chest pain observation unit compared with routine care. BMJ. 2004;328(7434):254.PubMedCrossRef Goodacre S, Nicholl J, Dixon S, et al. Randomised controlled trial and economic evaluation of a chest pain observation unit compared with routine care. BMJ. 2004;328(7434):254.PubMedCrossRef
30.
go back to reference College van Zorgverzekeraars: Handboek voor kostenonderzoek 2004 van het College van Zorgverzekeraars. 2009. College van Zorgverzekeraars: Handboek voor kostenonderzoek 2004 van het College van Zorgverzekeraars. 2009.
31.
go back to reference Nederlands Zorgautoriteit: Tarieflijst zorginstellingen 2009 from the Nederlands Zorgautoriteit. 2009. Nederlands Zorgautoriteit: Tarieflijst zorginstellingen 2009 from the Nederlands Zorgautoriteit. 2009.
33.
go back to reference Busschbach J, Rabin R, De Charro F, Proceedings of the 24th Scientific Plenary Meeting of the EuroQol Group. Kijkduin. In EuroQoL: The Hague, the Netherlands; 2007. Busschbach J, Rabin R, De Charro F, Proceedings of the 24th Scientific Plenary Meeting of the EuroQol Group. Kijkduin. In EuroQoL: The Hague, the Netherlands; 2007.
34.
go back to reference Lamers LM, Stalmeier PF, McDonnell J, et al. Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff. Ned Tijdschr Geneeskd. 2005;149(28):1574–8.PubMed Lamers LM, Stalmeier PF, McDonnell J, et al. Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff. Ned Tijdschr Geneeskd. 2005;149(28):1574–8.PubMed
35.
go back to reference Califf RM, Lokhnygina Y, Cannon CP, et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. Am Heart J. 2010;159(5):705–9.PubMedCrossRef Califf RM, Lokhnygina Y, Cannon CP, et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. Am Heart J. 2010;159(5):705–9.PubMedCrossRef
Metagegevens
Titel
Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia
Auteurs
F. van Nooten
G. M. Davies
J. W. Jukema
A. H. Liem
E. Yap
X. H. Hu
Publicatiedatum
01-02-2011
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Netherlands Heart Journal / Uitgave 2/2011
Print ISSN: 1568-5888
Elektronisch ISSN: 1876-6250
DOI
https://doi.org/10.1007/s12471-010-0061-5

Andere artikelen Uitgave 2/2011

Netherlands Heart Journal 2/2011 Naar de uitgave

Rhythm Puzzle - Answer

Answer to the Rhythm Puzzle